NEW YORK CITY -- Almost a quarter of surveyed U.S. adults met criteria for generalized anxiety disorder (GAD), though the vast majority of them were undiagnosed, a retrospective cross-sectional study ...

A clinical trial’s encouraging results won US Food and Drug Administration breakthrough therapy status for an LSD formulation to treat generalized anxiety disorder, Mind Medicine Inc. announced ...

Please provide your email address to receive an email when new articles are posted on . MM-120 demonstrated clinically and statistically significant reductions in anxiety compared with placebo at 12 ...

Forbes contributors publish independent expert analyses and insights. I write about Black and neurodivergent identity in the workplace. If you have anxiety, know that you are not alone. Anxiety ...

The device is designed to transcutaneously deliver low-level electrical stimulation to the skin behind the ears. The Food and Drug Administration (FDA) has cleared Modius Stress, a transdermal, ...

Findings showed the 100mcg dose met the primary endpoint demonstrating a statistically significant 7.6-point reduction in HAM-A score at week 4 compared with placebo. The Food and Drug Administration ...

In a world of constant connectivity and mounting pressures, generalized anxiety disorder (GAD) has emerged as a significant mental health challenge affecting millions. Recent studies show that anxiety ...

Anxiety isn’t just about feeling stressed or worried. For millions of Americans it’s a daily battle that affects everything from relationships to career choices. With 31% of adults experiencing an ...

Individuals with generalized anxiety disorder (GAD), a condition characterized by daily excessive worry lasting at least six months, have a high relapse rate even after receiving treatment. Artificial ...

Generalized anxiety disorder affects 1 in 20 U.S. adults. Those with serious symptoms may isolate themselves to the point they rarely leave their home and are unable to work and build meaningful ...

Shares of Mind Medicine (NASDAQ:MNMD) surged around 16% premarket on Thursday after the U.S. Food and Drug Administration (FDA) granted breakthrough designation to its MM120 (lysergide d-tartrate) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PsiGAD psilocybin-assisted therapy demonstrated a ...